281 related articles for article (PubMed ID: 27100794)
41. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
42. Calreticulin mutations and long-term survival in essential thrombocythemia.
Tefferi A; Wassie EA; Lasho TL; Finke C; Belachew AA; Ketterling RP; Hanson CA; Pardanani A; Gangat N; Wolanskyj AP
Leukemia; 2014 Dec; 28(12):2300-3. PubMed ID: 24791854
[TBL] [Abstract][Full Text] [Related]
43. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
44. CALR and ASXL1 mutation analysis in 190 patients with essential thrombocythemia.
Shen H; Chao H; Ding Z; Feng Y; Cen J; Pan J; He J; Zhou M; Chen Z; Chen S
Leuk Lymphoma; 2015 Mar; 56(3):820-2. PubMed ID: 25005031
[No Abstract] [Full Text] [Related]
45. MPL W515L mutation in pediatric essential thrombocythemia.
Farruggia P; D'Angelo P; La Rosa M; Scibetta N; Santangelo G; Lo Bello A; Duner E; Randi ML; Putti MC; Santoro A
Pediatr Blood Cancer; 2013 Aug; 60(8):E52-4. PubMed ID: 23441089
[TBL] [Abstract][Full Text] [Related]
46. Thrombocytosis in an infant with high thrombopoietin concentrations.
Hankins J; Naidu P; Rieman M; Wang W; Kaushansky K; Rodriguez-Galindo C
J Pediatr Hematol Oncol; 2004 Feb; 26(2):142-5. PubMed ID: 14767209
[TBL] [Abstract][Full Text] [Related]
47. Thrombocytosis and STAT5 activation in chronic myelogenous leukaemia are not associated with JAK2 V617F or calreticulin mutations.
Turakhia SK; Murugesan G; Cotta CV; Theil KS
J Clin Pathol; 2016 Aug; 69(8):713-9. PubMed ID: 26754830
[TBL] [Abstract][Full Text] [Related]
48. Germline MPL mutations may be a rare cause of "triple-negative" thrombocytosis.
Borsani O; Pietra D; Casetti IC; Vanni D; Riccaboni G; Catricalà S; Grazia B; Boveri E; Arcaini L; Rumi E
Exp Hematol; 2024 Jan; 129():104127. PubMed ID: 37939832
[TBL] [Abstract][Full Text] [Related]
49. Analysis of thrombopoietin and c-mpl expression in a child with essential thrombocythemia.
Yoshida N; Ishii E; Koga N; Kamimura T; Miyazaki S
Pediatr Hematol Oncol; 1998; 15(4):359-63. PubMed ID: 9658438
[TBL] [Abstract][Full Text] [Related]
50. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
Ha JS; Kim YK
Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
[TBL] [Abstract][Full Text] [Related]
51. Two faces of ET: CALR and JAK2.
Chao MP; Gotlib J
Blood; 2014 Mar; 123(10):1438-40. PubMed ID: 24627549
[TBL] [Abstract][Full Text] [Related]
52. Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.
Langabeer SE; Haslam K; McMahon C
Pediatr Blood Cancer; 2015 Jan; 62(1):175-6. PubMed ID: 25132652
[No Abstract] [Full Text] [Related]
53. Platelets from Calreticulin mutated essential thrombocythemia patients are less reactive than JAK2 V617F mutated platelets.
Hauschner H; Bokstad Horev M; Misgav M; Nagar M; Seligsohn U; Rosenberg N; Koren-Michowitz M
Am J Hematol; 2020 Apr; 95(4):379-386. PubMed ID: 31868244
[TBL] [Abstract][Full Text] [Related]
54. [Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
Krähling T; Balassa K; Meggyesi N; Bors A; Csomor J; Bátai Á; Halm G; Egyed M; Fekete S; Reményi P; Masszi T; Tordai A; Andrikovics H
Orv Hetil; 2014 Dec; 155(52):2074-81. PubMed ID: 25528320
[TBL] [Abstract][Full Text] [Related]
55. Clinical effect of CALR allele burden in patients with essential thrombocythemia.
Bertozzi I; Biagetti G; Vezzaro T; Barzon I; Carraro M; Fabris F; Randi ML
Ann Hematol; 2022 Jun; 101(6):1345-1346. PubMed ID: 34743237
[No Abstract] [Full Text] [Related]
56. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms.
Araki M; Yang Y; Masubuchi N; Hironaka Y; Takei H; Morishita S; Mizukami Y; Kan S; Shirane S; Edahiro Y; Sunami Y; Ohsaka A; Komatsu N
Blood; 2016 Mar; 127(10):1307-16. PubMed ID: 26817954
[TBL] [Abstract][Full Text] [Related]
57. A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.
Lambert MP; Jiang J; Batra V; Wu C; Tong W
Am J Hematol; 2012 May; 87(5):532-4. PubMed ID: 22389068
[TBL] [Abstract][Full Text] [Related]
58. Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene.
Kondo T; Okabe M; Sanada M; Kurosawa M; Suzuki S; Kobayashi M; Hosokawa M; Asaka M
Blood; 1998 Aug; 92(4):1091-6. PubMed ID: 9694695
[TBL] [Abstract][Full Text] [Related]
59. Essential thrombocythaemia.
Double G; Harrison C
Hematology; 2015 Mar; 20(2):119-20. PubMed ID: 25715049
[No Abstract] [Full Text] [Related]
60. Hereditary erythrocytosis, thrombocytosis and neutrophilia.
Hong WJ; Gotlib J
Best Pract Res Clin Haematol; 2014 Jun; 27(2):95-106. PubMed ID: 25189721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]